GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cynata Therapeutics Ltd (STU:51S) » Definitions » YoY EBITDA Growth

Cynata Therapeutics (STU:51S) YoY EBITDA Growth : 20.00% (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Cynata Therapeutics YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Cynata Therapeutics's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was 20.00%.

Cynata Therapeutics's EBITDA per Share for the six months ended in Dec. 2023 was €-0.02.


Cynata Therapeutics YoY EBITDA Growth Historical Data

The historical data trend for Cynata Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cynata Therapeutics YoY EBITDA Growth Chart

Cynata Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 28.33 -46.51 -9.52 39.13

Cynata Therapeutics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.84 14.29 -53.85 20.00 55.00

Cynata Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Cynata Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Jun. 2023 is calculated as:

YoY EBITDA Growth (A: Jun. 2023 )
=(EBITDA per Share (A: Jun. 2023 )-EBITDA per Share (A: Jun. 2022 ))/ | EBITDA per Share (A: Jun. 2022 ) |
=(-0.069--0.063)/ | -0.063 |
=-9.52 %

Cynata Therapeutics's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (Q: Dec. 2023 )
=(EBITDA per Share (Q: Dec. 2023 )-EBITDA per Share (Q: Dec. 2022 )) / | EBITDA per Share (Q: Dec. 2022 )) |
=(-0.024--0.03)/ | -0.03 |
=20.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cynata Therapeutics YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Cynata Therapeutics's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Cynata Therapeutics Business Description

Traded in Other Exchanges
Address
100 Cubitt Street, Level 3, Cremorne, VIC, AUS, 3121
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.

Cynata Therapeutics Headlines

No Headlines